Company / Financials
NORTHWEST BIOTHERAPEUTICS INC Financials
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$1.4M
FY2025 · -0.3% YoY
Net Income
-$60.2M
FY2025 · +28.2% YoY
Profit Margin
-4365.9%
FY2025 · net income / revenue
ROE
-
FY2025 · return on equity
Total Assets
$81.3M
FY2025
Total Debt
$60.0M
-1.00x debt/equity
Equity
-$60.3M
FY2025
ROA
-74.0%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -18.88 (distress zone, below 1.23 threshold)
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$1.4M-0.3% YoYNet Income HistoryProfit after all expenses and taxes-$60.2M+28.2% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$59.9M+9.9% YoYSG&A Expense HistorySelling, general, and administrative expenses$32.5M-1.5% YoYR&D Expense HistoryResearch and development spending$28.8M-17.5% YoYInterest Expense HistoryCost of borrowing and debt obligations-Income Tax HistoryTotal income tax expense-$537.0KEPS (Basic) HistoryBasic earnings per share-$0.07-16.7% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$0.07-16.7% YoYShares Outstanding HistoryWeighted average diluted shares outstanding1.3B+13.0% YoY